Another New CAR-T Therapy in China is Fast-Tracking Approval, Targeting Pediatric Acute Lymphoblastic Leukemia(ALL) with a 100% Response Rate!

Another New CAR-T Therapy in China is Fast-Tracking Approval, Targeting Pediatric Acute Lymphoblastic Leukemia with a 100% Response Rate!

ALL

In recent years, CAR-T cell therapies from China have garnered global attention in the fight against cancer, and now another CAR-T product is about to hit the market. Priscabtagene Autoleucel Injection (pCAR-19B), developed by China’s Precision Biotech, is specifically designed for relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) and is currently under priority review for approval. It is poised to become China’s first CAR-T therapy specifically tailored for children and adolescents with acute leukemia.

This groundbreaking therapy has shown remarkable efficacy, achieving a 100% overall response rate in early clinical trials. For patients who no longer respond to conventional treatments, Priscabtagene Autoleucel offers a new lifeline. The therapy has demonstrated superior safety and efficacy in clinical settings, thanks to gene optimization and advanced vector systems that reduce side effects while enhancing effectiveness.

Currently, pCAR-19B has entered Phase II clinical trials, expanding its scope beyond children to include adult patients with relapsed leukemia. It is also being researched for the treatment of other malignant lymphomas, such as diffuse large B-cell lymphoma and follicular lymphoma. This signifies the vast potential of CAR-T therapies in China, promising more effective treatment options for blood cancer patients both domestically and globally.

Precision Biotech’s CAR-T therapy is expected to gain approval soon, contributing to global medical innovation while bringing new hope to countless patients.

To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of Advanced Medicine in China for preliminary evaluation!

WhatsApp: Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com